Biogen bullish on prospects of Alzheimer's drug aducanumab by Nick Paul Taylor Friday, November 22, 2019 Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i
